论文部分内容阅读
目的探讨可手术乳腺癌新辅助化疗的疗效。方法联合吡柔比星、氟尿嘧啶、环磷酰胺或序贯紫杉类药物方案治疗Ⅰ-ⅢC期乳腺癌,术前化疗2～10周期观察疗效。结果超声评判化疗4周期后CTFci方案和CTF方案差异均有统计学意义,4周期后超声评价疗效,总有效率60%,疾病控制率96%,乳腺癌保乳18.4%,病理pCR12%,ER/PR(-)的患者化疗后达到pCR有显著统计学意义。结论联合化疗用于浸润性乳腺癌的术前化疗,可有效控制肿瘤,提高保乳率。化疗可使ER/PR(-)及浸润性导管癌更易达到pCR。
Objective To investigate the efficacy of neoadjuvant chemotherapy for operable breast cancer. Methods Combination of pirarubicin, fluorouracil, cyclophosphamide or sequential taxane regimen for treatment of stage Ⅰ-ⅢC breast cancer, preoperative chemotherapy for 2 to 10 cycles to observe the effect. Results After 4 cycles of chemotherapy, CTFci regimen and CTF regimen showed statistically significant differences. After 4 cycles, the therapeutic effect was evaluated by ultrasound. The total effective rate was 60%, the disease control rate was 96%, breast conserving milk was 18.4%, pathology pCR12%, ER / PR (-) patients achieved pCR after chemotherapy was statistically significant. Conclusion Combined chemotherapy for invasive breast cancer preoperative chemotherapy can effectively control the tumor and improve the rate of breast-conserving. Chemotherapy can make pCR easier for ER / PR (-) and invasive ductal carcinoma.